Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — FY2024 Earnings Presentation

42 slides from Day One Biopharmaceuticals's earnings presentation, Feb 25, 2025

  1. Slide 1: Targeted therapies for people of all ages

    Targeted therapies for people of all ages February 2025 Day One Biopharmaceuticals

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Inspired by the urgent needs of children

    Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life-threatening diseases

  4. Slide 4: Bringing life-changing medicines to patients sooner

    Bringing life-changing medicines to patients sooner Commercial-stage biopharmaceutical company Our goal is to develop and provide access to targeted new medicines to patients of all ages as rapidly as possible Focused on advancing first- or best-in-class medicines for childhood and adult diseases Wh

  5. Slide 5: Day One's Future Potential Value creation

    Day One’s Future Potential Value creation Continued revenue growth from OJEMDA globally Indication expansion in front-line pLGG with FIREFLY-2 Generate clinical POC data in DAY301 program Fund pipeline expansion Focused capital allocation, leveraging our efficient operating model to maintain strong

  6. Slide 6: Pipeline and anticipated milestones

    Product Candidate Therapeutic Area Preclinical Phase 1 Phase 2 Phase 3/ Registrational Approved Recent & Anticipated Milestones Tovorafenib3 Type II RAF Inhibitor OJEMDA brand name in U.S.1 Ex-U.S. Rights: BRAF-altered relapsed pLGG FDA accelerated approval April 2024 Ex-U.S. license agreement July

  7. Slide 7: Relapsed or refractory BRAF-altered pLGG OJEMDA

    Relapsed or refractory BRAF-altered pLGG OJEMDA Nora Living with pLGG

  8. Slide 8: A serious and life-threatening disease

    A serious and life-threatening disease *Incidence of BRAF alterations varies across pLGG subtypes. 1 Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol. 2009;24(11):1397-1408. doi:10.1177/0883073809342005. 2 Penman CL et al. Front Oncol. 2015;5:54. 3 Cohen AR., N Engl J Med. 2020;386

  9. Slide 9: Burden of treatment in pediatric low-grade glioma

    Source: 1. Heitzer AM, Raghubar K, Ris MD, et al. Neuropsychological functioning following surgery for pediatric low-grade glioma: a prospective longitudinal study. J Neurosurg Pediatr. 2019;1-9. doi:10.3171/2019.9.PEDS19357. 2. Bryant R. Managing side effects of childhood cancer treatment. J Pediat

  10. Slide 10: Available in tablet and pediatric-friendly powder for oral suspension

    Available in tablet formulation and pediatric-friendly powder for oral suspension Overview U.S. prescribing information for OJEMDA Indication OJEMDA is indicated for the treatment of pediatric patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF

  11. Slide 11: 51% overall response rate (RAPNO-LGG)

    51% Overall response rate (RAPNO-LGG) in 76 evaluable patients Response (IRC) RAPNO-LGG n n (%) 95% CI ORR, n (%) BRAF fusion or rearrangement BRAF V600 mutation Prior MAPKi use MAPKi-naïve Median DOR, months Median TTR, months Range 76 64 12 45 31 39 39 39 (51) 33 (52) 6 (50) 22 (49) 17 (55) 13.8 5

  12. Slide 12: Warnings and Precautions; TEAEs

    Warnings and Precautions Hemorrhage Skin toxicity, including photosensitivity Hepatotoxicity Effect on growth Embryo-fetal toxicity Use in NF1- associated tumors No boxed warnings or contraindications TEAEs (≥ 30% of patients [n=137]) Preferred Term, n (%) Any Grade Grade ≥3 Any AE 137 (100) 86 (63)

  13. Slide 13: pLGG epidemiology and addressable opportunity

    1 US Census. 2 CBTRUS, Qaddoumi et al 2009, Schreck et al 2019, ClearView Analysis. 3 Penman CL et al. Front Oncol. 2015;5:54. 4 Cohen AR., N Engl J Med. 2020;386(20):1922-1931. 5 Lassaletta A, et al. J Clin Oncol. 2017;35(25):2934-2941. 6 Faulkner C, et al. J Neuropathol Exp Neurol. 2015;74(9):867-

  14. Slide 14: Data from Pivotal Phase FIREFLY-1 trial

    Data from Pivotal Phase 2 FIREFLY-1 trial. Meaningful tumor stabilization or shrinkage may be possible with OJEMDA, in the clinical trial: 51% of children experienced tumor shrinkage by at least 25% 82% of children saw their tumors shrink or remain stable Efficacy Safety Generally well-tolerated the

  15. Slide 15: OJEMDA launch update by the numbers

    $57.2M 2024 OJEMDA Net Product Revenues $29.0M Q4 2024 OJEMDA Net Product Revenues 1,647 Cumulative 2024 Prescriptions Since Launch1,2 1 OJEMDA received approval in April 2024 and is indicated for the treatment of pediatric patients 6 months of age and older with relapsed or refractory pediatric low

  16. Slide 16: OJEMDA Revenue Strong Uptake Continues

    1 OJEMDA received U.S. FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma on April 23, 2024. 2 In December 2024, the Centers for Medicare & Medicaid Services (CMS) agreed that OJEMDA is approved exclusively for pediatric indications, reducing its Medicaid and

  17. Slide 17: Breadth and depth of prescribing since launch

    1 Analysis includes on-label, non-EAP patients only and data are approximations based on SP reporting as of December 31, 2024. 100% Goal Breadth of Accounts Treating ≥ 1 Patient on OJEMDA1 (N = 17) (N = 85) (N = 110) Launch Dec 2024 1 Patient 2 Patients 3+ Patients OJEMDA U.S. prescriptions continue

  18. Slide 18: Coverage approval rates remain high

    Coverage approval rates remain high across both Commercial and Medicaid payers Reported Coverage1,2 Percent of Covered Lives – Commercial & Medicaid Covered ~76% (+12%) Not Covered Pending Review 1% Not Published 23% ~60% Commercial Patients ~40% Medicaid Patients Payer Mix On-label patients approve

  19. Slide 19: OJEMDA priorities to drive revenue growth in 2025

    Continue to increase breadth and depth of prescribers Establish OJEMDA as standard of care in 2nd line relapsed or refractory BRAF-altered pLGG Support prescribers and patients to allow for optimal duration of treatment OJEMDA priorities to drive revenue growth in 2025

  20. Slide 20: Pivotal Phase 3 trial of tovorafenib in front-line pLGG FIREFLY-2

    Pivotal Phase 3 trial of tovorafenib in front-line pLGG FIREFLY-2 Bradon Living with pLGG since age 11

  21. Slide 21: FIREFLY-2 trial design and endpoints

    Trial design Endpoints Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib vs SoC chemotherapy Eligibility: Patients aged up to <25 years with LGG harboring a RAF alteration and requiring first-line systemic therapy Tovorafenib available as tablets and pediatric-friendly liqu

  22. Slide 22: PTK7-targeted antibody-drug conjugate (ADC) DAY301

    PTK7-targeted antibody-drug conjugate (ADC) DAY301

  23. Slide 23: Substantial development and commercial potential for DAY301

    Substantial development and commercial potential for DAY301 Novel ADC active in preclinical models, designed to maximize therapeutic window PTK7: clinically-validated ADC target Anti-tumor activity of anti-PTK7 ADC demonstrated in Phase 1b trial of Pfizer / Abbvie’s cofetuzumab pelidotin1 DAY301: po

  24. Slide 24: Opportunity for a next-generation PTK7 ADC

    Potential opportunity for a next-generation PTK7 ADC with improved therapeutic index Clinical results for cofetuzumab pelidotin1 demonstrated proof of concept for PTK7-targeted ADCs Cofetuzumab pelidotin activity seen in multiple tumor types: Ovarian (Pt-resistant): ORR 27% (n=63) TNBC: ORR 21% (n=2

  25. Slide 25: DAY301 designed to maximize therapeutic index

    DAY301 has been designed to maximize therapeutic index and overcome limitations of prior programs Tumor regression at tolerable doses seen in multiple preclinical models Higher HNSTD in cyno toxicology studies; payload with known safety profile High cell permeability / bystander effect; low efflux (

  26. Slide 26: Preclinical tumor volume data

    0 1,000 2,000 3,000 0 20 40 60 80 Tumor Volume (mm3) (Mean ± SEM) Days Post Administration 0 1,000 2,000 3,000 4,000 0 7 14 21 28 Tumor Volume (mm3) (Mean ± SEM) Days Post Administration *P 0.0435 0 400 800 1,200 1,600 2,000 2,400 0 7 14 21 28 35 *P 0.0316 Tumor Volume (mm3) (Mean ± SEM) Days Post A

  27. Slide 27: PTK7 expression across indications

    Indication PTK7 Expression (>1+) U.S. Patient Population Cases/Deaths ORR at Relapse Median OS at Relapse Endometrial 100%2 67,880/13,2503 39%7 9 months7 Esophageal SCC​ 76%1 22,370/16,1303 5%4 3 months4 Gastric 35%2 26,890/10,8803 12%14 6-14 months15 Head & Neck SCC 75%1 54,540/11,5803 32%5 7.8 mon

  28. Slide 28: DAY301 Phase 1 trial design

    Phase 1a: Monotherapy Dose Escalation FDA-cleared starting dose DL5 RD1 RD2 Identify two recommended dose levels for further evaluation, based on safety and anti-tumor activity BOIN design for efficiency of dose escalation Backfill active dose levels to generate additional safety data Enroll tumor t

  29. Slide 29: Summary

    Summary

  30. Slide 30: Fourth quarter & full year 2024 financial results

    Fourth quarter & full year 2024 financial results Financial Summary ($ in millions) Three Months Ended 12/31/24 Three Months Ended 12/31/23 Full Year Ended 12/31/24 Full Year Ended 12/31/23 OJEMDA Net Revenue 29.0 -- 57.2 -- License Revenue 0.2 -- 73.9 -- Total Revenue $29.2 $-- $131.2 $-- Cost of P

  31. Slide 31: Well positioned for sustainable growth and long-term success

    Inserted messaging but need help with formatting. Day One is well positioned for sustainable growth and long-term success Drive OJEMDA revenue growth Execute on clinical development pipeline for FIREFLY-2 and DAY301 Leverage our development and commercialization expertise to further expand our multi

  32. Slide 32: Appendix

    Appendix

  33. Slide 33: Tovorafenib type II RAF inhibitor mechanism

    Tovorafenib is an investigational, oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase Activity in tumors driven by both RAF fusions and BRAF V600E mutations Tablet and pediatric-friendly liquid suspension Once weekly dosing Curren

  34. Slide 34: FIREFLY-1 trial design

    Three arm, open-label, global registrational phase 2 trial Pivotal Arm 1 (recurrent/progressive pLGG, n=77): harboring a KIAA1549-BRAF fusion or BRAF V600E mutation Arm 2 (expanded access recurrent/progressive LGG, n=60): harboring an activating RAF alteration Arm 3 (extracranial solid tumors): harb

  35. Slide 35: Data from pivotal phase trial FIREFLY-1

    Data from pivotal phase 2 trial June 5, 2023 data cutoff FIREFLY-1

  36. Slide 36: Baseline patient characteristics

    Characteristic Arm 1 (n=77) Median age, years (range) 8 (2-21) Sex, n (%) Male Female 40 (52) 37 (48) Race, n (%) White Asian Black Multiple Other Not specified 41 (53) 5 (6) 2 (3) 3 (4) 6 (8) 20 (26) Number of lines of prior systemic therapy Median (range) 1, n (%) 2, n (%) ≥3, n (%) 3 (1-9) 17 (22

  37. Slide 37: Maximum change in tumor size and response

    Maximum change in tumor size (%) RAPNO-LGG Maximum change in tumor size (%) RANO-LGG Maximum change in tumor size (%) RANO-HGG June 5, 2023 data cutoff. BOR, best overall response; CBR, clinical benefit rate; CI, confidence interval; CR, complete response; DOR, duration of response; HGG, high-grade

  38. Slide 38: Treatment duration, RAPNO-LGG evaluable

    5.3 Months 13.8 Months Median time to response Median duration of treatment Duration of tovorafenib therapy for all patients with RAPNO-LGG evaluable lesions Patients Overall treatment duration (months) June 5, 2023 data cutoff.

  39. Slide 39: Treatment duration, RANO-HGG evaluable

    June 5, 2023 data cutoff. 3.0 Months 16.6 Months Median time to response Median duration of treatment Duration of tovorafenib therapy for all patients with RANO-HGG evaluable lesions Patients Overall treatment duration (months)

  40. Slide 40: Treatment duration, RANO-LGG evaluable

    June 5, 2023 data cutoff. Patients Overall treatment duration (months) 5.5 Months 14.4 Months Median time to response Median duration of treatment Duration of tovorafenib therapy for all patients with RANO-LGG evaluable lesions

  41. Slide 41: Response by assessment criteria

    RAPNO-LGG2 RANO-LGG3,4 RANO-HGG1 Response (IRC) n n n ORR,* n (%) 76 39 (51) 76 40 (53) 69 46 (67) BRAF fusion 64 33 (52) 64 33 (52) 59 41 (69) BRAF mutation 12 6 (50) 12 7 (58) 10 5 (50) Prior MAPKi 45 22 (49) 45 23 (51) 41 29 (71) MAPKi-naive 31 17 (55) 31 17 (55) 28 17 (61) CBR,* n (%) (SD of any

  42. Slide 42: TEAEs and TRAEs

    TEAEs TRAEs Preferred Term, n (%) Any Grade Grade ≥3 Any Grade Grade ≥3 Any AE 137 (100) 86 (63) 134 (98) 58 (42) Hair color changes 104 (76) 0 104 (76) 0 Anemia 81 (59) 15 (11) 67 (49) 14 (10) Elevated CPK 80 (58) 16 (12) 77 (56) 16 (12) Fatigue 76 (55) 6 (4) 60 (44) 6 (4) Vomiting 68 (50) 6 (4) 28

Day One Biopharmaceuticals — FY2024 Earnings Presentation on 6ix